Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudwaleit

Showing results (51-60 of 136) with videos related to

Pageof 14
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritisder Heijde D van, J Braun, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|May 15, 2002
Synovial T cell proliferation to the Yersinia enterocolitica 19 kDa antigen differentiates yersinia triggered reactive arthritis (ReA) from ReA triggered by other enterobacteriaH Appel, M Rudwaleit, P Wu, et al.
Annals of the Rheumatic Diseases|March 22, 2005
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximabX Baraliakos, J Listing, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|April 18, 2002
T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesisJ Zou, M Rudwaleit, A Thiel, et al.
Annals of the Rheumatic Diseases|March 22, 2005
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanerceptM Rudwaleit, X Baraliakos, J Listing, et al.
Annals of the Rheumatic Diseases|November 18, 2004
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitisJ Listing, J Brandt, M Rudwaleit, et al.
Clinical and Experimental Rheumatology|June 21, 2008
Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practiceH Haibel, I H Song, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|April 15, 2004
How to diagnose axial spondyloarthritis earlyM Rudwaleit, D van der Heijde, M A Khan, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]U Kiltz, M Rudwaleit, J Sieper, et al.
Annals of the Rheumatic Diseases|November 17, 2007
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitisM Rudwaleit, S Schwarzlose, E S Hilgert, et al.
Pageof 14

Showing results (51-60 of 136) with videos related to

Sort By:
Pageof 14
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritisder Heijde D van, J Braun, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|May 15, 2002
Synovial T cell proliferation to the Yersinia enterocolitica 19 kDa antigen differentiates yersinia triggered reactive arthritis (ReA) from ReA triggered by other enterobacteriaH Appel, M Rudwaleit, P Wu, et al.
Annals of the Rheumatic Diseases|March 22, 2005
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximabX Baraliakos, J Listing, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|April 18, 2002
T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesisJ Zou, M Rudwaleit, A Thiel, et al.
Annals of the Rheumatic Diseases|March 22, 2005
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanerceptM Rudwaleit, X Baraliakos, J Listing, et al.
Annals of the Rheumatic Diseases|November 18, 2004
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitisJ Listing, J Brandt, M Rudwaleit, et al.
Clinical and Experimental Rheumatology|June 21, 2008
Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practiceH Haibel, I H Song, M Rudwaleit, et al.
Annals of the Rheumatic Diseases|April 15, 2004
How to diagnose axial spondyloarthritis earlyM Rudwaleit, D van der Heijde, M A Khan, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]U Kiltz, M Rudwaleit, J Sieper, et al.
Annals of the Rheumatic Diseases|November 17, 2007
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitisM Rudwaleit, S Schwarzlose, E S Hilgert, et al.
Pageof 14